Please confirm you are human (Sign Up for free to never see this)
← Back to Search
Prognostic Significance Of Ki67 Expression In Malignant Peritoneal Mesothelioma
K. Pillai, M. Pourgholami, T. Chua, D. Morris
Published 2015 · Medicine
Save to my Library
Download PDFAnalyze on Scholarcy
Objectives:Although Ki67 measurement by immunohistochemistry has been widely used as a prognostic index in cancers, it has not been reported in malignant peritoneal mesothelioma (MPM). Hence, this study examines the prognostic significance of Ki67 in MPM. Methods:Specimens from 42 MPM patients were screened for Ki67 expression using immunohistochemistry. Ki67 expression was classified into 2 groups on the basis of expression (<25%=low; ≥25%=high) using standard methods. Using Kaplan-Meier survival analysis, the significance of Ki67 was assessed in different clinicopathologic categories. Results:High expression of Ki67 (≥25% by immunohistochemical evaluation) was correlated with poor survival in the overall group (P=0.001); male sex (P=0.001); female sex (P=0.001); epithelioid tumors (P=0.001): male epithelioid (P=0.001), female epithelioid (P=0.003); peritoneal cancer index (PCI): PCI<20 (P=0.001), PCI≥20 (P=0.002); and age at diagnosis (AAD): AAD<60 years (P=0.001), AAD≥60 years (P=0.004). Independent of Ki67, male sex (P=0.007), sarcomatoid histology (P=0.001), PCI≥20 (P=0.013), and AAD≥60 years (P=0.004) correlated with poor survival. Multivariate analysis showed that only AAD≥60 years (P=0.049) and high Ki67 expression for all tumors (P=0.031), male sex (P=0.038), female sex (P=0.021), epithelioid tumors (P=0.044), and AAD<60 years (P=0.029) were statistically significant. Conclusions:Ki67 expression affects prognosis in MPM patients and helps to predict survival within the various clinicopathologic categories.
This paper references
Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation
J. Gerdes (1983)
The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer
R. Jones (2008)
Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small‐volume or low‐grade prostate cancer
T. Zellweger (2009)
Oestrogen receptors are prognostic factors in malignant peritoneal mesothelioma
K. Pillai (2013)
Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial.
M. Baum (2002)
17β-Estradiol Promotes Breast Cancer Cell Proliferation-Inducing Stromal Cell-Derived Factor-1-Mediated Epidermal Growth Factor Receptor Transactivation: Reversal by Gefitinib Pretreatment
A. Pattarozzi (2008)
Prognostic Analysis of Clinicopathologic Factors in 49 Patients With Diffuse Malignant Peritoneal Mesothelioma Treated With Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion
M. Deraco (2006)
Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies.
J. Gerdes (1990)
Diagnosing and treating testosterone deficiency in different parts of the world. Results from global market research
L. Gooren (2007)
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.
T. Yan (2009)
Prognostic significance of histomorphologic parameters in diffuse malignant peritoneal mesothelioma.
C. Cerruto (2006)
Ki-67 as a molecular target for therapy in an in vitro three-dimensional model for ovarian cancer.
R. Rahmanzadeh (2010)
Malignant mesothelioma of the peritoneum: case reports and immunohistochemical findings including Ki-67 expression
H. Hirano (2009)
Clinical implications of novel activating EGFR mutations in malignant peritoneal mesothelioma
J. Foster (2010)
The Ki‐67 protein: From the known and the unknown
T. Scholzen (2000)
The murine Ki-67 cell proliferation antigen accumulates in the nucleolar and heterochromatic regions of interphase cells and at the periphery of the mitotic chromosomes in a process essential for cell cycle progression.
M. Starborg (1996)
The effect of age and gender on outcome after treatment for colon carcinoma. A population-based study in the Uppsala and Stockholm region.
B. V. van Leeuwen (2008)
Population-based cancer survival trends in England and Wales up to 2007: an assessment of the NHS cancer plan for England.
B. Rachet (2009)
A novel tumor‐node‐metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi‐institutional database *
T. Yan (2011)
Quantitative live imaging of cancer and normal cells treated with Kinesin-5 inhibitors indicates significant differences in phenotypic responses and cell fate
J. D. Orth (2008)
Peritoneal mesothelioma: current understanding and management
T. Chua (2009)
Immunohistochemical staining of mucin 1 in prostate tissues.
N. Rabiau (2009)
The proliferation markers Ki-67/MIB-1, phosphohistone H3, and survivin may contribute in the identification of aggressive ovarian carcinomas.
Guro Aune (2011)
Surgical biology for the clinician: peritoneal mesothelioma: current understanding and management.
T. Chua (2009)
Impact of age at diagnosis on prostate cancer treatment and survival.
Seth K. Bechis (2011)
Ki-67 detects a nuclear matrix-associated proliferation-related antigen. I. Intracellular localization during interphase.
R. Verheijen (1989)
Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67.
J. Gerdes (1984)
Effect of young age on prostate cancer survival: a population-based assessment (United States)
R. Merrill (2004)
Navitoclax (ABT-263) accelerates apoptosis during drug-induced mitotic arrest by antagonizing Bcl-xL.
Jue Shi (2011)
Estrogen receptor-beta affects the prognosis of human malignant mesothelioma.
G. Pinton (2009)
Predicting survival in malignant mesothelioma
A. Musk (2011)
Prognostic Indicators for Patients Undergoing Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma†
T. Yan (2006)
Functional aptamers and aptazymes in biotechnology, diagnostics, and therapy.
M. Famulok (2007)
Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer
J. Yang (2006)
Colorectal carcinomas with high MIB‐1 labelling indices but low pKi67 mRNA levels correlate with better prognostic outcome
M. Duchrow (2003)
Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment
P. Fasching (2011)
The proliferation rate paradox in antimitotic chemotherapy
T. Mitchison (2012)
Ki-67 expression in gastric cancer. Results from a prospective study with long-term follow-up.
D. Lazăr (2010)
Prognostic value of Ki67 expression after short-term presurgical endocrine therapy for primary breast cancer.
M. Dowsett (2007)
High Wilms’ tumour gene (WT1) expression and low mitotic count are independent predictors of survival in diffuse peritoneal mesothelioma
A. Scattone (2012)
Importance of gender in diffuse malignant peritoneal mesothelioma.
C. Cao (2012)
Differential Expression of Ki-67 and Sex Steroid Hormone Receptors Between Genders in Peritoneal Mesothelioma
Terence C. Chua (2009)
Prognostic value of a combined estrogen receptor, progesterone receptor, Ki-67, and human epidermal growth factor receptor 2 immunohistochemical score and comparison with the Genomic Health recurrence score in early breast cancer.
J. Cuzick (2011)
Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer.
F. Penault-Llorca (2009)
Risk Factors and Clinicopathological Study of Prognostic Factors in the Peritoneal Mesothelioma
E. C. Tudor (2010)
This paper is referenced by
Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases
David B. Chapel (2020)
Ki67 Proliferation Index as a Histopathological Predictive and Prognostic Parameter of Oral Mucosal Melanoma in Patients without Distant Metastases
X. Ma (2017)
Standardizing of Mesothelioma and Pseudomyxoma Care
Ranyell Spencer Sobreira Batista (2019)
A proposal of Brazilian Society of Surgical Oncology (BSSO/SBCO) for standardizing cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and malignant peritoneal mesothelioma
T. Batista (2017)
A proposal of Brazilian Society of Surgical Oncology for standardizing cytoreductive surgery plus hypertermic intraperitoneal chemotherapy procedures in Brazil : pseudomixoma peritonei , appendiceal tumors and malignant peritoneal mesothelioma
P. Batista (2017)
Molecular pathways and diagnosis in malignant mesothelioma: A review of the 14th International Conference of the International Mesothelioma Interest Group.
D. Chapel (2019)
Manejo del mesotelioma peritoneal maligno con citorreducción quirúrgica más quimioterapia hipertérmica intraperitoneal en el Instituto Nacional de Cancerología, Colombia: reporte de un caso y revisión bibliográfica
Juliana Restrepo lópez (2019)
Deep learning-based classification of mesothelioma improves prediction of patient outcome
Pierre Courtiol (2019)
Prognostic Value of Ki67 Percentage, WT-1 Expression and p16/CDKN2A Deletion in Diffuse Malignant Peritoneal Mesothelioma: A Single-Centre Cohort Study
Federica Pezzuto (2020)
Patient Selection for Cytoreductive Surgery.
T. Grotz (2018)
Targeting mesothelin receptors with drug-loaded bacterial nanocells suppresses human mesothelioma tumour growth in mouse xenograft models
M. Alfaleh (2017)
The potential utility of GATA3 for diagnosis of malignant pleural mesotheliomas.
Sarita Prabhakaran (2020)
Outcomes of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma and predictors of survival
S. N. Gilani (2018)
Predictive and Prognosis Factors of Clinical Utility in Mesothelioma
Rodríguez-Cid Jeronimo Rafael (2020)